Neurogene (NASDAQ: NGNE) posts 2026 corporate update and presentation

Rhea-AI Filing Summary

Neurogene Inc. filed a current report to let investors know it has issued a new press release and updated its corporate presentation. On January 12, 2026, the company released a press statement providing recent corporate updates and anticipated milestones for the coming year, which is included as Exhibit 99.1. On the same date, Neurogene posted an updated corporate presentation on its website, furnished as Exhibit 99.2. The company notes that this information is being furnished, not filed, under the Exchange Act, meaning it is not automatically subject to certain liability provisions or incorporated into other SEC filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 12, 2026

Neurogene Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-36327			98-0542593
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)

535 W 24th Street, 5th Floor

New York, NY 10011

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (877) 237-5020

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.000001 par value

NGNE

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, Neurogene Inc. (the “Company”) issued a press release providing recent corporate updates and anticipated milestones for the coming year. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on January 12, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibits 99.1 amd 99.2 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 or 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Description
99.1						Press Release dated January 12, 2026
99.2						Corporate Presentation (January 2026)
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			NEUROGENE INC.
Date: January 12, 2026			By:			/s/ Christine Mikail
						Name: Christine Mikail
						Title: President, Chief Financial Officer

FAQ

What did Neurogene (NGNE) report in this 8-K filing?

Neurogene Inc. reported that on January 12, 2026 it issued a press release with recent corporate updates and anticipated milestones for the coming year and posted an updated corporate presentation on its website.

Which exhibits are included in Neurogene’s January 12, 2026 8-K?

The 8-K includes Exhibit 99.1, a press release dated January 12, 2026, Exhibit 99.2, a January 2026 corporate presentation, and Exhibit 104, the cover page interactive data file.

How does Neurogene classify the information in Item 7.01 of this 8-K?

Neurogene states that the information in Item 7.01 and Exhibits 99.1 and 99.2 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act.

Are Neurogene’s press release and presentation incorporated into other SEC filings?

Neurogene specifies that the press release and presentation will not be incorporated by reference into any Exchange Act or Securities Act filing except where expressly set forth by specific reference.

What is the main focus of Neurogene’s new corporate presentation?

The filing states that the January 2026 corporate presentation provides updated corporate information and anticipated milestones, but it does not describe the detailed contents of the presentation.